REGN
Regeneron PharmaceuticalsNASDAQHealth CareBiotechnologySnapshot 2026-05-08
As of May 8, 2026, REGN has a composite score of 17.6 and a signal label of "mild favorable." This score is influenced by a high confidence level of 81.4 and a guidance credibility of 100.0. Key drivers include macroeconomic factors such as labor, rates, growth, and inflation, with a moderate risk label and a fair valuation score of 59.5.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)0.11
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $10.58 → $10.88 (+2.9% / 30d). 10 raised, 12 cut, 23 covering analysts.
0 upgrades, 0 downgrades / 30d, 8 maintained. 76% of analysts rate Buy.
6 PT revisions / 30d. Avg target 21.6% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
No recent events recorded.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Maintain GAAP gross margin guidancecostmixed65% progress
4/29: “GAAP gross margin on net product sales 79%-80% 77%-78%.”
Why this status
Stated in 3 of last 3 quarters. The GAAP gross margin guidance for 2026 is 79%-80%. Previous quarters showed a margin of approximately 82%-83%. The trajectory is consistent with maintaining the guidance.
- 2.Manage capital expenditurescapital allocationmixed35% progress
4/29: “Capital expenditures $1.100–$1.300 billion $1.100–$1.200 billion.”
Why this status
Stated in 3 of last 3 quarters. Capital expenditures guidance for 2026 is $1.100–$1.300 billion. Previous guidance was $850–$950 million. The trajectory shows an increase in planned expenditures, indicating a focus on managing within the new range.
- 3.Control GAAP effective tax ratecostmixed65% progress
4/29: “GAAP effective tax rate 12%-14% Unchanged.”
Why this status
Stated in 3 of last 3 quarters. The GAAP effective tax rate guidance for 2026 is 12%-14%. Previous quarters showed a rate of approximately 11%-14%. The trajectory is consistent with controlling the tax rate within the guided range.
Guidance track record
Last 6 quarters of EPS guidance with actuals.
Per-quarter detail
| Period | Guidance | Actual | Result |
|---|---|---|---|
| 2023-12-31 | $-0.21 | $11.86 | beat |
| 2024-06-30 | $-0.18 | $11.56 | beat |
| 2024-09-30 | $-0.43 | $12.46 | beat |
| 2025-09-30 | $-0.68 | $11.83 | beat |
| 2025-12-31 | $-0.14 | $11.44 | beat |
| 2026-03-31 | $-0.81 | $9.47 | beat |
Beat / inside / miss is computed from the guided range when issued; for point-estimate quarters a ±5% tolerance band around the mid is used. surprise_pct_vs_mid is unstable when guided EPS is near zero, so it is not surfaced as a headline.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 31%; 252d 39%.
Drawdown — Max 1y −21%. Bad day move −3%.
Beta to sector ETF (XLV) — 1.15 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 35/100, drawdown 57/100, beta 85/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 6 guided quarters · 4441.3% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Maintain GAAP gross margin guidance
CostNew since 2026-05-04Regeneron aims to maintain its GAAP gross margin on net product sales within the guided range.
On track →MixedStated in 3 of last 3 quarters. The GAAP gross margin guidance for 2026 is 79%-80%. Previous quarters showed a margin of approximately 82%-83%. The trajectory is consistent with maintaining the guidance.
65%CEO/CFO:“GAAP gross margin on net product sales 79%-80% 77%-78%.”Multiple sourcesSource dated 2026-04-29Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q1Multiple sources
“GAAP gross margin on net product sales 79%-80% 77%-78%.”
- 2025-Q4Multiple sources
“GAAP gross margin on net product sales Approximately 83% Approximately 82%.”
- 2025-Q3Multiple sources
“GAAP gross margin on net product sales 83%-84% Approximately 83%.”
- #2
Manage capital expenditures
Capital allocationNew since 2026-05-04Regeneron is focused on managing its capital expenditures within the guided range.
Behind →MixedStated in 3 of last 3 quarters. Capital expenditures guidance for 2026 is $1.100–$1.300 billion. Previous guidance was $850–$950 million. The trajectory shows an increase in planned expenditures, indicating a focus on managing within the new range.
35%CEO/CFO:“Capital expenditures $1.100–$1.300 billion $1.100–$1.200 billion.”Multiple sourcesSource dated 2026-04-29Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q1Multiple sources
“Capital expenditures $1.100–$1.300 billion $1.100–$1.200 billion.”
- 2025-Q4Multiple sources
“Capital expenditures $880–$950 million $850–$890 million.”
- 2025-Q3Multiple sources
“Capital expenditures * $850–$950 million $880–$950 million.”
- #3
Control GAAP effective tax rate
CostNew since 2026-05-04Regeneron aims to control its GAAP effective tax rate within the guided range.
On track →MixedStated in 3 of last 3 quarters. The GAAP effective tax rate guidance for 2026 is 12%-14%. Previous quarters showed a rate of approximately 11%-14%. The trajectory is consistent with controlling the tax rate within the guided range.
65%CEO/CFO:“GAAP effective tax rate 12%-14% Unchanged.”Multiple sourcesSource dated 2026-04-29Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q1Multiple sources
“GAAP effective tax rate 12%-14% Unchanged.”
- 2025-Q4Multiple sources
“GAAP effective tax rate 11%-13% Approximately 14%.”
- 2025-Q3Multiple sources
“GAAP effective tax rate 9%-11%.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
68 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
REGN Regeneron Pharmaceuticals | +18 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-29)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-29)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-299d agoItem 2.02
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
earnings preannouncementneutralscore 53 - 2026-04-081mo agoItem 2.02
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $102 million on a pre-tax basis. This charge primarily relates to premium on equity securiti…
earnings preannouncementneutralscore 33 - 2026-01-303mo agoItem 2.02
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
earnings preannouncementneutralscore 7 - 2025-10-067mo agoItem 2.02
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2025 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $83 million on a pre-tax basis. This charge primarily relates to the previously disclosed $8…
earnings preannouncementpositivescore 1
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.